<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692250</url>
  </required_header>
  <id_info>
    <org_study_id>CHOL00207</org_study_id>
    <secondary_id>EudraCT 2007-003724-38</secondary_id>
    <nct_id>NCT00692250</nct_id>
  </id_info>
  <brief_title>A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers</brief_title>
  <official_title>A Phase I Open Label, Randomised, Single Dose, 2-way Crossover, 2-Sequence Pharmacokinetic Study on the Interaction of Colesevelam and Ciclosporin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess any potential interaction between colesevelam and
      ciclosporin in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability of Ciclosporin (AUC(0-t), AUC(âˆž) and C(max))</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam hydrochloride film-coated tablets (Cholestagel)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a body mass index (BMI) between 19 and 25 inclusive

          -  Medically healthy subjects with clinically normal laboratory profiles, physical exams,
             vital signs and ECGs.

          -  Give voluntary written informed consent to participate in the study

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic renal,
             hematologic, gastrointestinal (inclusive of dysphagia, swallowing disorders, severe
             gastrointestinal motility disorders), endocrine, immunologic, dermatologic,
             neurologic, infectious, or psychiatric disease.

          -  In addition, history or presence of: Alcoholism or drug abuse within the past year; OR
             hypersensitivity or idiosyncratic reaction to ciclosporin or other immunosuppressive
             agents; OR Chronic infection

          -  Subjects who ere tested positive at screening for HIV, HBsAg or HCV

          -  Subjects who received injectable corticosteroids in the 12 weeks preceding the first
             dose.

          -  Subjects who are allergic to castor oil or corn oil

          -  Subjects whose sitting blood pressure is less than 110/60 mmHg at screening or 100/55
             mmHg before dosing

          -  Subjects who have used any medications or substances known to be strong inhibitors of
             CYP3A enzymes within 10 days prior to the first dose.

          -  Subjects who have used any medications or substances known to be strong inducers of
             CYP3A enzymes within 28 days prior to the first dose.

          -  Subjects who have used antibiotics within 14 days prior to the first dose.

          -  Subjects who have used other medication (including over-the-counter products) vitamins
             and herbal products within 7 days prior to the first dose.

          -  Subjects who have used any live attenuated vaccine within 7 days prior to the first
             dose or are planning to use within 14 days after the end of the study.

          -  Subjects who, prior to informed consent, would have donated in excess of: 500mL of
             blood in 14 days;1500mL of blood in 180 days; OR 2500mL of blood in 1 year.

          -  Subjects who have participated in another clinical trial: within a period less or
             equal to 2 half live (t1/2) of the previous investigational product used OR within 60
             days prior to first dose.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen- Biotech Center</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Corporation</organization>
  </responsible_party>
  <keyword>Familial Hypercholesterolemia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

